Partner Mike Okaty discussed important legal issues for senior housing providers in a Senior Housing News article, “New Entrants, RIDEA Among Hot Topics in Senior Housing Legal Landscape.”
Okaty said he anticipates an increase in regulations in the future. “As more people move into senior living communities, as more of these communities exist, there’s going to be more of a need and an opportunity for new regulations,” he said.
Okaty also said it’s important to recognize that senior housing is not a risk-free business. “That said, there are all kinds of best practices for risk mitigation,” he said. “There are best practices for staffing, oversight, quality control, acuity testing to make sure people are in the appropriate level of care.”
Okaty said he anticipates an increase in regulations in the future. “As more people move into senior living communities, as more of these communities exist, there’s going to be more of a need and an opportunity for new regulations,” he said.
Okaty also said it’s important to recognize that senior housing is not a risk-free business. “That said, there are all kinds of best practices for risk mitigation,” he said. “There are best practices for staffing, oversight, quality control, acuity testing to make sure people are in the appropriate level of care.”
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.